Advanced search
Publication Cover
Emerging Microbes & Infections Volume 8, 2019 - Issue 1
Submit an article Journal homepage
1,804
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques

Xi Yanga University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Xiang Wangb Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Yufeng Songc Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People’s Republic of ChinaView further author information
,
Ping Zhoua University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Dapeng Lia University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Chao Zhanga University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Xia Jina University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
,
Zhong Huanga University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaView further author information
&
Dongming Zhoua University of Chinese Academy of Sciences, Beijing, People’s Republic of China;b Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of China;d Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1086-1097 | Received 09 Mar 2019, Accepted 11 Jul 2019, Published online: 24 Jul 2019

References

  • Bowen ET, Lloyd G, Harris WJ, et al. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet. 1977 Mar 12;1(8011):571–573. PubMed PMID: 65662. doi: 10.1016/S0140-6736(77)92001-3
  • Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015 Nov;13(11):663–676. DOI:10.1038/nrmicro3524 PubMed PMID: 26439085; PubMed Central PMCID: PMCPMC5201123.
  • Feldmann H, Jones S, Klenk HD, et al. Ebola virus: from discovery to vaccine. Nat Rev Immunol. 2003 Aug;3(8):677–685. DOI:10.1038/nri1154. PubMed PMID: 12974482.
  • Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014 Oct 9;371(15):1418–1425. DOI:10.1056/NEJMoa1404505. PubMed PMID: 24738640.
  • WorldHealthOrganization. Ebola situation report 30 March 2016 [Report]. Available from: http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016
  • Cenciarelli O, Gabbarini V, Pietropaoli S, et al. Viral bioterrorism: learning the lesson of Ebola virus in West Africa 2013–2015. Virus Res. 2015 Dec 2;210:318–326. DOI:10.1016/j.virusres.2015.09.002. PubMed PMID: 26359111.
  • Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov;13(11):1267–1277. DOI:10.1128/CVI.00162-06. PubMed PMID: 16988008; PubMed Central PMCID: PMCPMC1656552.
  • Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007 Nov 15;196(Suppl 2):S430–S437. DOI:10.1086/520583. PubMed PMID: 17940980.
  • Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017 Jan 26;376(4):330–341. DOI:10.1056/NEJMoa1414216. PubMed PMID: 25830322; PubMed Central PMCID: PMCPMC5408576.
  • Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015 Jun 6;385(9984):2272–2279. DOI:10.1016/S0140-6736(15)60553-0. PubMed PMID: 25817373.
  • Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med. 2017 Mar 9;376(10):928–938. DOI:10.1056/NEJMoa1410863. PubMed PMID: 25426834.
  • Winslow RL, Milligan ID, Voysey M, et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 Year. JAMA. 2017 Mar 14;317(10):1075–1077. DOI:10.1001/jama.2016.20644. PubMed PMID: 28291882.
  • Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016 Apr 28;374(17):1635–1646. DOI:10.1056/NEJMoa1411627. PubMed PMID: 25629663; PubMed Central PMCID: PMCPMC5798586.
  • Mercknewsroom. (2018). Merck begins rolling submission of licensure application for V920 (rVSVΔG-ZEBOV-GP) to U.S. Food and Drug Administration KENILWORTH, N.J. Available from: Available from: https://www.mrknewsroom.com/news-release/ebola/merck-begins-rolling-submission-licensure-application-v920-rvsvΔg-zebov-gp-us-foo
  • CFDA. (2017). The first recombinant Ebola virus vaccine was approved for new drug registration. Available from: http://samr.cfda.gov.cn/WS01/CL0050/178705.html
  • Shukarev G, Callendret B, Luhn K, et al. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Hum Vaccin Immunother. 2017 Feb;13(2):266–270. DOI:10.1080/21645515.2017.1264755. PubMed PMID: 27925844; PubMed Central PMCID: PMCPMC5328205.
  • Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001 Dec;75(23):11603–11613. DOI:10.1128/JVI.75.23.11603-11613.2001. PubMed PMID: 11689642; PubMed Central PMCID: PMCPMC114747.
  • Tatsis N, Tesema L, Robinson ER, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2006 Mar;13(5):421–429. DOI:10.1038/sj.gt.3302675. PubMed PMID: 16319951.
  • Li D, Chen T, Hu Y, et al. An Ebola virus-like particle-based reporter system Enables Evaluation of Antiviral Drugs In vivo under Non-biosafety level 4 conditions. J Virol. 2016 Oct 1;90(19):8720–8728. DOI:10.1128/JVI.01239-16. PubMed PMID: 27440895; PubMed Central PMCID: PMCPMC5021419.
  • Vitelli A, Folgori A, Scarselli E, et al. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane. Expert Rev Vaccines. 2017 Dec;16(12):1241–1252. DOI:10.1080/14760584.2017.1394842. PubMed PMID: 29047309.
  • Wang Y, Li J, Hu Y, et al. Ebola vaccines in clinical trial: the promising candidates. Hum Vaccin Immunother. 2017 Jan 2;13(1):153–168. DOI:10.1080/21645515.2016.1225637. PubMed PMID: 27764560; PubMed Central PMCID: PMCPMC5287303.
  • Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006 Mar 15;346(2):394–401. DOI:10.1016/j.virol.2005.10.042. PubMed PMID: 16356525.
  • Cheng T, Song Y, Zhang Y, et al. A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget. 2017 Apr 18;8(16):26871–26885. DOI:10.18632/oncotarget.15845. PubMed PMID: 28460470; PubMed Central PMCID: PMCPMC5432303.
  • Yang Y, Chi Y, Tang X, et al. Rapid, efficient, and Modular Generation of adenoviral vectors via Isothermal Assembly. Curr Protoc Mol Biol. 2016 04 January;113(1):16.26.1–16.26.8. doi: 10.1002/0471142727.mb1626s113
  • Chen T, Li D, Song Y, et al. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. Antiviral Res. 2017 Sep;145:54–59. DOI:10.1016/j.antiviral.2017.07.009. PubMed PMID: 28733113.
  • Zhang Q, Gui M, Niu X, et al. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep. 2016 May 16;6:25856. DOI:10.1038/srep25856. PubMed PMID: 27181584; PubMed Central PMCID: PMCPMC4867612.
  • Wang X, Xing M, Zhang C, et al. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect. 2014 May;3(5):e30. DOI:10.1038/emi.2014.30. PubMed PMID: 26038738; PubMed Central PMCID: PMCPMC4051363.
  • Wang X, Fu W, Yuan S, et al. Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge. Sci Rep. 2017 May 12;7(1):1854. DOI:10.1038/s41598-017-02019-1. PubMed PMID: 28500340; PubMed Central PMCID: PMCPMC5431854.
  • Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988 Jul 21;334(6179):255–258. DOI:10.1038/334255a0. PubMed PMID: 2456466.
  • Takada A, Watanabe S, Ito H, et al. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology. 2000 Dec 5;278(1):20–26. DOI:10.1006/viro.2000.0601. PubMed PMID: 11112476.
  • Rivera A, Messaoudi I. Molecular mechanisms of Ebola pathogenesis. J Leukoc Biol. 2016 Nov;100(5):889–904. DOI:10.1189/jlb.4RI0316-099RR. PubMed PMID: 27587404.
  • Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008 Nov;4(11):e1000225. DOI:10.1371/journal.ppat.1000225. PubMed PMID: 19043556; PubMed Central PMCID: PMCPMC2582959.
  • Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011 Nov;204(Suppl 3):S1066–S1074. DOI:10.1093/infdis/jir348. PubMed PMID: 21987743; PubMed Central PMCID: PMCPMC3203393.
  • Marzi A, Robertson SJ, Haddock E, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015 Aug 14;349(6249):739–742. DOI:10.1126/science.aab3920. PubMed PMID: 26249231.
  • Schuit M, Miller DM, Reddick-Elick MS, et al. Differences in the Comparative stability of Ebola virus Makona-C05 and Yambuku-Mayinga in blood. PLoS One. 2016;11(2):e0148476. DOI:10.1371/journal.pone.0148476. PubMed PMID: 26849135; PubMed Central PMCID: PMCPMC4744009.
  • Marzi A, Feldmann F, Hanley PW, et al. Delayed disease progression in cynomolgus macaques infected with Ebola virus Makona strain. Emerg Infect Dis. 2015 Oct;21(10):1777–1783. DOI:10.3201/eid2110.150259. PubMed PMID: 26402165; PubMed Central PMCID: PMCPMC4593438.
  • Wong G, Qiu X, de La Vega MA, et al. Pathogenicity comparison between the Kikwit and Makona Ebola virus variants in rhesus macaques. J Infect Dis. 2016 Oct 15;214(suppl 3):S281–S289. DOI:10.1093/infdis/jiw267. PubMed PMID: 27651412; PubMed Central PMCID: PMCPMC5050479.
  • Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola virus disease survivors – final report. N Engl J Med. 2017 Oct 12;377(15):1428–1437. DOI:10.1056/NEJMoa1511410. PubMed PMID: 26465681; PubMed Central PMCID: PMCPMC5798881.
  • Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002 Mar;76(6):2667–2675. PubMed PMID: 11861833; PubMed Central PMCID: PMCPMC135983. doi: 10.1128/JVI.76.6.2667-2675.2002
  • Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004 Oct;10(4):616–629. DOI:10.1016/j.ymthe.2004.07.013. PubMed PMID: 15451446.
  • Ewer K, Sebastian S, Spencer AJ, et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum Vaccin Immunother. 2017 Dec 2;13(12):3020–3032. DOI:10.1080/21645515.2017.1383575. PubMed PMID: 29083948; PubMed Central PMCID: PMCPMC5718829.
  • Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014 Oct;20(10):1126–1129. DOI:10.1038/nm.3702. PubMed PMID: 25194571.
  • Reyes-Sandoval A, Sridhar S, Berthoud T, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol. 2008 Mar;38(3):732–741. DOI:10.1002/eji.200737672. PubMed PMID: 18266272.
  • Feng Y, Li C, Hu P, et al. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerg Microbes Infect. 2018 Jun 6;7(1):101. DOI:10.1038/s41426-018-0102-5. PubMed PMID: 29872043; PubMed Central PMCID: PMCPMC5988821.
  • Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011 Aug 21;17(9):1128–1131. DOI:10.1038/nm.2447. PubMed PMID: 21857654.
  • Dahlke C, Lunemann S, Kasonta R, et al. Comprehensive characterization of cellular immune responses following Ebola virus infection. J Infect Dis. 2017 Jan 15;215(2):287–292. DOI:10.1093/infdis/jiw508. PubMed PMID: 27799354.
  • Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 2012 Oct 31;4(158):158ra146. DOI:10.1126/scitranslmed.3004582. PubMed PMID: 23115355; PubMed Central PMCID: PMCPMC3789651.
  • Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013 Nov 28;3:3365. DOI:10.1038/srep03365. PubMed PMID: 24284388; PubMed Central PMCID: PMCPMC3842534.
  • Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014 Oct 2;514(7520):47–53. DOI:10.1038/nature13777. PubMed PMID: 25171469; PubMed Central PMCID: PMCPMC4214273.
  • Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis. 2015 Oct 1;212(Suppl 2):S91–S97. DOI:10.1093/infdis/jiv284. PubMed PMID: 26063223; PubMed Central PMCID: PMCPMC4564553.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.